OBJECTIVE: To investigate the safety, tolerability, and pharmacokinetics of the anti-tumor necrosis factor-alpha monoclonal antibody infliximab in subjects with intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD). STUDY DESIGN: We conducted a multicenter, randomized, prospective trial of second IVIG infusion (2 g/kg) versus infliximab (5 mg/kg) in 24 children with acute KD and fever after initial treatment with IVIG. Primary outcome measures were the safety, tolerability, and pharmacokinetics of infliximab. Secondary outcome measures were duration of fever and changes in markers of inflammation. RESULTS: Study drug infusions were associated with cessation of fever within 24 hours in 11 of 12 subjects treated with infliximab and in 8 of 12 subjects retreated with IVIG. No infusion reactions or serious adverse events were attributed to either study drug. No significant differences were observed between treatment groups in the change from baseline for laboratory variables, fever, or echocardiographic assessment of coronary arteries. CONCLUSIONS: Both infliximab and a second IVIG infusion were safe and well tolerated in the subjects with KD who were resistant to standard IVIG treatment. The optimal management of patients resistant to IVIG remains to be determined.
RCT Entities:
OBJECTIVE: To investigate the safety, tolerability, and pharmacokinetics of the anti-tumor necrosis factor-alpha monoclonal antibody infliximab in subjects with intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD). STUDY DESIGN: We conducted a multicenter, randomized, prospective trial of second IVIG infusion (2 g/kg) versus infliximab (5 mg/kg) in 24 children with acute KD and fever after initial treatment with IVIG. Primary outcome measures were the safety, tolerability, and pharmacokinetics of infliximab. Secondary outcome measures were duration of fever and changes in markers of inflammation. RESULTS: Study drug infusions were associated with cessation of fever within 24 hours in 11 of 12 subjects treated with infliximab and in 8 of 12 subjects retreated with IVIG. No infusion reactions or serious adverse events were attributed to either study drug. No significant differences were observed between treatment groups in the change from baseline for laboratory variables, fever, or echocardiographic assessment of coronary arteries. CONCLUSIONS: Both infliximab and a second IVIG infusion were safe and well tolerated in the subjects with KD who were resistant to standard IVIG treatment. The optimal management of patients resistant to IVIG remains to be determined.
Authors: Stephen B Hanauer; Carrie L Wagner; Mohan Bala; Lloyd Mayer; Suzanne Travers; Robert H Diamond; Allan Olson; Warren Bao; Paul Rutgeerts Journal: Clin Gastroenterol Hepatol Date: 2004-07 Impact factor: 11.382
Authors: Jane W Newburger; Masato Takahashi; Michael A Gerber; Michael H Gewitz; Lloyd Y Tani; Jane C Burns; Stanford T Shulman; Ann F Bolger; Patricia Ferrieri; Robert S Baltimore; Walter R Wilson; Larry M Baddour; Matthew E Levison; Thomas J Pallasch; Donald A Falace; Kathryn A Taubert Journal: Circulation Date: 2004-10-26 Impact factor: 29.690
Authors: Nicolino Ruperto; Daniel J Lovell; Ruben Cuttica; Nick Wilkinson; Patricia Woo; Graciela Espada; Carine Wouters; Earl D Silverman; Zsolt Balogh; Michael Henrickson; Maria-Teresa Apaz; Eileen Baildam; Anders Fasth; Valeria Gerloni; Pekka Lahdenne; Anne-Marie Prieur; Angelo Ravelli; Rotraud K Saurenmann; Maria Luz Gamir; Nico Wulffraat; Laszlo Marodi; Ross E Petty; Rik Joos; Francesco Zulian; Deborah McCurdy; Barry L Myones; Kalman Nagy; Peter Reuman; Ilona Szer; Suzanne Travers; Anna Beutler; Greg Keenan; Jason Clark; Sudha Visvanathan; Adedigbo Fasanmade; Aparna Raychaudhuri; Alan Mendelsohn; Alberto Martini; Edward H Giannini Journal: Arthritis Rheum Date: 2007-09
Authors: Brian W McCrindle; Jennifer S Li; L LuAnn Minich; Steven D Colan; Andrew M Atz; Masato Takahashi; Victoria L Vetter; Welton M Gersony; Paul D Mitchell; Jane W Newburger Journal: Circulation Date: 2007-06-18 Impact factor: 29.690
Authors: Robert Baldassano; Christian P Braegger; Johanna C Escher; Kimberly DeWoody; David F Hendricks; Gregory F Keenan; Harland S Winter Journal: Am J Gastroenterol Date: 2003-04 Impact factor: 10.864
Authors: E William St Clair; Carrie L Wagner; Adedigbo A Fasanmade; Benjamin Wang; Thomas Schaible; Arthur Kavanaugh; Edward C Keystone Journal: Arthritis Rheum Date: 2002-06
Authors: Chiea Chuen Khor; Sonia Davila; Willemijn B Breunis; Yi-Ching Lee; Chisato Shimizu; Victoria J Wright; Rae S M Yeung; Dennis E K Tan; Kar Seng Sim; Jie Jin Wang; Tien Yin Wong; Junxiong Pang; Paul Mitchell; Rolando Cimaz; Nagib Dahdah; Yiu-Fai Cheung; Guo-Ying Huang; Wanling Yang; In-Sook Park; Jong-Keuk Lee; Jer-Yuarn Wu; Michael Levin; Jane C Burns; David Burgner; Taco W Kuijpers; Martin L Hibberd Journal: Nat Genet Date: 2011-11-13 Impact factor: 38.330